PEOPLE - Changes at Abbott Laboratories:
This article was originally published in Clinica
Executive Summary
Abbott Laboratories executive vice-president of the $4bn diagnostics division Edward Michael and executive vice-president of $1.1bn vascular medical devices division John Capek are among the group's four directors who will report directly to CEO Miles White following the sudden retirement of group No 2, COO Richard Gonzalez. Abbott is now committed to growing the diagnostics operation, after the recent collapse of GE's proposed $8.13bn takeover, but it has slipped to third in the world rankings, behind Roche and the Dade Behring-enhanced Siemens Medical Solutions Diagnostics.
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.